Arbutus reports Q1 net loss $24.5M; imdusiran functionally cures 8 cHBV patients

Arbutus Biopharma Corp

2025-Q1 EPS reported -$0.13 revenue$1,764,000

Net loss $24.5M ($0.13/share) vs $17.9M ($0.10) in Q1 2024; revenue $1.8M vs $1.5M.
Cash, equivalents & securities $112.7M as of Mar 31, down from $122.6M at Dec 31, 2024.
Imdusiran combo therapy functionally cured 8 cHBV patients to date; 2 received no interferon.
AB-101 oral PD-L1 inhibitor achieved 100% receptor occupancy in 11 of 13 healthy subjects at 40mg.
Moderna U.S. jury trial set for Sep 29, 2025; claim construction for Pfizer/BioNTech expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.